<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03537586</url>
  </required_header>
  <id_info>
    <org_study_id>18-00116</org_study_id>
    <nct_id>NCT03537586</nct_id>
  </id_info>
  <brief_title>A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction</brief_title>
  <official_title>A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Among patients with stable ischemic heart disease who are referred for coronary angiography,&#xD;
      a substantial proportion have non-obstructive coronary artery disease (CAD). Ischemia based&#xD;
      on symptoms or stress testing may be due to coronary microvascular dysfunction in up to 40%&#xD;
      of these patients. However, the mechanisms and optimal treatment of coronary microvascular&#xD;
      dysfunction are unknown. Aberrant platelet activity and inflammation have been hypothesized&#xD;
      as mechanisms of microvascular dysfunction. Investigators plan to evaluate association&#xD;
      between platelet activity, inflammation, and coronary microvascular dysfunction in stable&#xD;
      women referred for coronary angiography, and to identify non-invasive correlates of coronary&#xD;
      microvascular dysfunction in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study are to&#xD;
&#xD;
        1. Investigate platelet activity and inflammation in patients with and without coronary&#xD;
           microvascular disease who are referred for coronary angiography for the evaluation of&#xD;
           stable ischemic heart disease and are found to have non-obstructuve epicardial CAD&#xD;
&#xD;
        2. To identify correlates of coronary microvascular dysfunction in non coronary&#xD;
           microvascular beds that can be characterized in vivo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Activity measured by the Index of Microcirculatory Resistance (IMR)</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of Inflammation measured by the Index of Microcirculatory Resistance (IMR)</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Microvascular Disease</condition>
  <condition>Ischemic Heart Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Non-Obstructive CAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After diagnostic coronary angiography, invasive measures of coronary microvascular physiology will be obtained. Blood will be collected for platelet activity, inflammation and isolation of coronary endothelial cells. Evaluation of the sublingual microvasculature with a side stream dark field imaging video microscope will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diagnostic Coronary Angiography with Non-Obstructive CAD</intervention_name>
    <description>Platelet activity in patients with and without CMVD (measured as a dichotomous variable) will be compared using the independent samples T-Test (for normally distributed data) of the Mean-Whitney U test.</description>
    <arm_group_label>Non-Obstructive CAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult women age ≥18 years referred for coronary angiography&#xD;
&#xD;
          -  Stable ischemic heart disease, defined by ischemic symptoms and/or myocardial ischemia&#xD;
             by stress testing&#xD;
&#xD;
          -  Administration of aspirin therapy prior to cardiac catheterization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pre-Cath Exclusion criteria:&#xD;
&#xD;
          -  Active bleeding and/or bleeding diathesis&#xD;
&#xD;
          -  Anemia (hemoglobin &lt;9 mg/dl)&#xD;
&#xD;
          -  Known thrombocytosis (platelet count &gt;500,000)&#xD;
&#xD;
          -  Know thrombocytopenia (platelet count &lt;100,000)&#xD;
&#xD;
          -  NSAIDs (e.g., ibuprofen, naproxen) within 3 days&#xD;
&#xD;
          -  Platelet antagonists other than aspirin and thienopyridines, within 7 days&#xD;
&#xD;
          -  Prior percutaneous coronary intervention or coronary artery bypass grafting&#xD;
&#xD;
          -  Acute myocardial infarction within 3 months&#xD;
&#xD;
          -  Severe valvular heart disease&#xD;
&#xD;
          -  Cardiogenic shock or mechanical circulatory support&#xD;
&#xD;
          -  New York Heart Association (NYHA) Functional Class III or IV heart failure&#xD;
&#xD;
          -  Ejection Fraction &lt;40%&#xD;
&#xD;
          -  Hypertrophic obstructive cardiomyopathy or severe left ventricular hypertrophy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Contraindication to intravenous infusion of adenosine during coronary angiography, due&#xD;
             to known hypersensitivity to adenosine, known or suspected bronchoconstrictive or&#xD;
             bronchospastic lung disease (severe asthma), second- or third-degree AV block (except&#xD;
             in patients with a functioning artificial pacemaker), or sinus node disease, such as&#xD;
             sick sinus syndrome or symptomatic bradycardia,&#xD;
&#xD;
        Angiographic Exclusion criteria:&#xD;
&#xD;
          -  Obstructive CAD (≥50% luminal obstruction in ≥1 major epicardial coronary arteries by&#xD;
             invasive coronary angiography)&#xD;
&#xD;
          -  Unfavorable coronary artery anatomy for guidewire positioning (as determined by the&#xD;
             angiographer or PI)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>125 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathaniel Smilowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathaniel Smilowitz</last_name>
    <phone>212-263-5656</phone>
    <email>Nathaniel.Smilowitz@nyulangone.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathaniel R Smilowitz</last_name>
      <phone>212-263-5656</phone>
      <email>Nathaniel.Smilowitz@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Nathaniel Smilowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Microvascular Angina</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

